

Yiling Pharma receives first international approval for herbal COVID-19 medicine

07 September 2020 | News

Lianhua Qingwen capsules - as a herbal medicine to be registered in Kuwait



China-based Yiling Pharmaceutical recently issued a notice that it had received a certificate of drug registration granted by the Pharmaceutical and Herbal Medicine Registration and Control Administration of Kuwait that certified its drug - Lianhua Qingwen capsules - as a herbal medicine to be registered in Kuwait.

It's the first time that Lianhua Qingwen has been granted permission in countries other than China to treat symptoms caused by mild and moderate cases of COVID-19.

Lianhua Qingwen is the leading product of Yiling Pharmaceutical. Since the initial outbreak of COVID-19, it's been recommended in the Diagnosis and Treatment Protocol for COVID-19 (Version 4/5/6/7/8) released by China's national authorities and in the diagnosis and treatment protocols in over 20 provinces in the country.

It's been widely used in hospitals designated for taking in and treating COVID-19 patients during the outbreak in China. The results of a prospective, randomized, controlled, and multi-center clinical study on treating COVID-19 with the TCM Lianhua Qingwen Capsules, which Academicians Zhong Nanshan, Li Lanjuan, and Zhang Boli and other experts worked on together with over 20 hospitals, were published in *Phytomedicine*, the journal with a high impact factor in the field of international herbal medicine.

It's found in the study in terms of clinical use that Lianhua Qingwen proved to be both safe and effective in treating COVID-19

in conjunction with conventional therapy as it could significantly relieve clinical symptoms of COVID-19 such as fever, debilitation, and cough, greatly improve pulmonary lesions, shorten the duration of symptoms, and increase the clinical recovery rate.